Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT05334368

PHASE3

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

Sponsor: GlaxoSmithKline

View on ClinicalTrials.gov

Summary

This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000 cells/ microliter (μL) during Screening. Historical HES flares are defined as documented HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy. Participants who meet the inclusion and exclusion criteria will be randomized in a 2:1 ratio to receive either depemokimab or placebo while continuing their SoC HES therapy.

Official title: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

123

Start Date

2022-09-06

Completion Date

2028-12-19

Last Updated

2025-11-25

Healthy Volunteers

Conditions

Hypereosinophilic Syndrome

Interventions

DRUG

Depemokimab

Depemokimab will be administered.

OTHER

Placebo

Matching placebo will be administered.

Inclusion Criteria: * Participants who are greater than or equal (\>=) 40 kilogram (kg) at Screening Visit 1. * Participants who have a documented diagnosis of HES prior to Visit 2. * A history of 2 or more HES flares within the past 12 months prior to Visit 1. * A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: a) woman of non-childbearing potential (WONCBP) Or b) woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (\<) 1 percentage (%). * Capable of giving signed informed consent. Exclusion Criteria: * Participants with HES disease manifestations which in the opinion of the investigator may put the participant at unacceptable risk from study participation or confound interpretation of efficacy or safety data. * Participants with chronic or ongoing active infections requiring systemic treatment or a pre-existing parasitic infestation within 6 months prior to Visit 1. * Participants with a known immunodeficiency (e.g., Human Immunodeficiency Virus \[HIV\]), other than that explained by the use of OCS or other therapy taken for HES. * Participants with a history of or current lymphoma. * Participants with current malignancy or previous history of cancer in remission for less than 5 years prior to Visit 1. Participants that had localized carcinoma (i.e., basal or squamous cell) of the skin which was resected for cure will not be excluded. * Participants with a haematologic malignancy with hypereosinophilia in which HES is not the primary diagnosis, e.g., chronic myeloid leukaemia, myelodysplastic syndrome, chronic eosinophilic leukaemia-not otherwise specified. * Cirrhosis or current unstable liver or biliary disease per investigator assessment. * Participants who have severe or clinically significant cardiovascular disease uncontrolled with standard treatment. * Participants with current diagnosis of vasculitis. * Hypereosinophila with no clinical symptoms and/or proof of organ dysfunction. * Clinical diagnosis of Eosinophilic granulomatosis with polyangiitis (EGPA). * Participants with an allergy/ intolerance to a monoclonal antibody or biologic, or any of the excipients of the investigational product. * Participants who have a previous documented failure with anti-interleukin (IL)-5/5R therapy. * Participants who have received monoclonal antibodies (mAb) within 30 days or 5 half-lives, whichever is longer, prior to Visit 1. * Participants who test positive for the FIP1L1-PDGFRα fusion gene. * QT interval corrected for heart rate according to Fridericia's formula (QTcF) ≥450 milliseconds (msec) or QTcF ≥480 msec for participants with Bundle Branch Block at Screening Visit 1. * Participants who are not responsive to OCS based on clinical response or blood eosinophil counts in the opinion of the Investigator. * Participants who are pregnant or breastfeeding.

Locations (91)

GSK Investigational Site

San Diego, California, United States

GSK Investigational Site

Atlanta, Georgia, United States

GSK Investigational Site

Boston, Massachusetts, United States

GSK Investigational Site

Southfield, Michigan, United States

GSK Investigational Site

Rochester, Minnesota, United States

GSK Investigational Site

Manhasset, New York, United States

GSK Investigational Site

Cincinnati, Ohio, United States

GSK Investigational Site

Columbus, Ohio, United States

GSK Investigational Site

Charleston, South Carolina, United States

GSK Investigational Site

Nashville, Tennessee, United States

GSK Investigational Site

Salt Lake City, Utah, United States

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Florida, Argentina

GSK Investigational Site

La Plata, Argentina

GSK Investigational Site

Mar del Plata, Argentina

GSK Investigational Site

Quilmes, Argentina

GSK Investigational Site

Garran, Australian Capital Territory, Australia

GSK Investigational Site

Brussels, Belgium

GSK Investigational Site

Porto Alegre, Rio Grande do Sul, Brazil

GSK Investigational Site

Blumenau, Brazil

GSK Investigational Site

Rio de Janeiro, Brazil

GSK Investigational Site

Sorocaba, Brazil

GSK Investigational Site

Ottawa, Ontario, Canada

GSK Investigational Site

Toronto, Ontario, Canada

GSK Investigational Site

Beijing, China

GSK Investigational Site

Changsha, China

GSK Investigational Site

Guangzhou, China

GSK Investigational Site

Guangzhou, China

GSK Investigational Site

Harbin, China

GSK Investigational Site

Nanchang, China

GSK Investigational Site

Shanghai, China

GSK Investigational Site

Suzhou, China

GSK Investigational Site

Wuhan, China

GSK Investigational Site

Brno-Bohunice, Czechia

GSK Investigational Site

Hradec Králové, Czechia

GSK Investigational Site

Prague, Czechia

GSK Investigational Site

Ústí nad Labem, Czechia

GSK Investigational Site

Odense C, Denmark

GSK Investigational Site

Bad Bramstedt, Germany

GSK Investigational Site

Mannheim, Germany

GSK Investigational Site

Athens, Greece

GSK Investigational Site

Rio Patras, Greece

GSK Investigational Site

Pokfulam, Hong Kong

GSK Investigational Site

Ramat Gan, Israel

GSK Investigational Site

Tel Aviv, Israel

GSK Investigational Site

Bologna, Italy

GSK Investigational Site

Catania, Italy

GSK Investigational Site

Milan, Italy

GSK Investigational Site

Naples, Italy

GSK Investigational Site

Novara, Italy

GSK Investigational Site

Pavia, Italy

GSK Investigational Site

Roma, Italy

GSK Investigational Site

Treviso, Italy

GSK Investigational Site

Verona, Italy

GSK Investigational Site

Aomori, Japan

GSK Investigational Site

Aomori, Japan

GSK Investigational Site

Chiba, Japan

GSK Investigational Site

Gifu, Japan

GSK Investigational Site

Hyōgo, Japan

GSK Investigational Site

Kanagawa, Japan

GSK Investigational Site

Miyagi, Japan

GSK Investigational Site

Tokyo, Japan

GSK Investigational Site

Tokyo, Japan

GSK Investigational Site

Wakayama, Japan

GSK Investigational Site

Yamanashi, Japan

GSK Investigational Site

Guadalajara, Mexico

GSK Investigational Site

Monterrey, Mexico

GSK Investigational Site

Veracruz, Mexico

GSK Investigational Site

Chęciny, Poland

GSK Investigational Site

Lodz, Poland

GSK Investigational Site

Bucharest, Romania

GSK Investigational Site

Cluj-Napoca, Romania

GSK Investigational Site

Gwangju, South Korea

GSK Investigational Site

Jeonju, South Korea

GSK Investigational Site

Kangwondo, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Suwon Kyunggi-do, South Korea

GSK Investigational Site

Barcelona, Spain

GSK Investigational Site

Granada, Spain

GSK Investigational Site

Madrid, Spain

GSK Investigational Site

Madrid, Spain

GSK Investigational Site

Pozuelo de AlarcOn Madr, Spain

GSK Investigational Site

Salamanca, Spain

GSK Investigational Site

Valencia, Spain

GSK Investigational Site

Zaragoza, Spain

GSK Investigational Site

Leicester, United Kingdom

Clinical Research Directory

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (91)